Vascular and Alzheimer's disease effects by the apoE derived ABCA1 agonist CS6253
28 August 2017 (14:00 - 18:00)
Organised by:
Abstract
About the speaker
Resverlogix Inc., San Francisco (United States of America)
33 More presentations in this session
Access the full session
The Event
ESC Congress 2017
28 August 2017
14:00 CET
